Ester Pérez-Martín

• PhD
• Torres Quevedo Postdoctoral Fellowship at Neuroscience Innovative Technologies

Introduction Immunotherapy for neurodegenerative diseases often induces severe side effects due to the interaction of monoclonal antibodies (mAb) with the immune and nervous systems. We present a novel platform based on an intrathecal device that clears target molecules from cerebrospinal fluid (CSF) without releasing mAb into the organism (pseudod...

In recent decades, the scientific community has faced a major challenge in the search for new therapies that can slow down or alleviate the process of neuronal death that accompanies neurodegenerative diseases. This study aimed to identify an effective therapy using neurotrophic factors to delay the rapid and aggressive cerebellar degeneration expe...

In recent decades, the scientific community has faced a major challenge in the search for new therapies that can slow down or alleviate the process of neuronal death that accompanies neurodegenerative diseases. This study aimed at identifying an effective therapy using neurotrophic factors to delay the rapid and aggressive cerebellar degeneration e...

Simple Summary The development of innovative therapeutic strategies involving chronic drug delivery to specific brain regions has been crucial in preclinical neuroscience. However, these strategies involve complex surgeries due to the need for implanting a drug storage system connected to the brain through a cannula while ensuring animal welfare, w...

Neurodegenerative diseases involve an exacerbated neuroinflammatory response led by microglia that triggers cytokine storm and leukocyte infiltration into the brain. PPARα agonists partially dampen this neuroinflammation in some models of brain insult, but neuronal loss was not the triggering cause in any of them. This study examines the anti-infla...

Intrathecal pseudodelivery is a new route of drug delivery to the CNS based on an implantable device endowed with a smart system of nanoporous membranes. We have developed a miniaturized prototype of the device for rodents. Here we present preliminary results on the use of antiAbeta mAbs intrathecally pseudodelivered in the APP/PS1 mouse model of A...

Current therapeutic approaches based on "one gene, one drug, one disease" philosophy usually offer limited benefits for the treatment of neurodegenerative diseases. However, little is known about the synergy of combined therapies. In this study, the possible synergistic effect of the combination of the endocannabinoid oleoylethanolamide (OEA) and d...

The progression of neurodegenerative diseases is reciprocally associated with impairments in peripheral immune responses. We investigated different contexts of selective neurodegeneration to identify specific alterations of peripheral immune cells and, at the same time, discover potential biomarkers associated to this pathological condition. Conseq...

The endocannabinoid oleoylethanolamide (OEA) has been proven to exert anti-inflammatory and neuroprotective effects in different animal models with brain injury of varied etiology. Indeed, a previous study of our laboratory demonstrated that the exogenous administration of OEA-prior to the onset of the neurodegenerative process-resulted in neuronal...

The endocannabinoid oleoylethanolamide (OEA) has proven to exert anti-inflammatory and neuroprotective effects in different animal models with brain injury of varied etiology. Indeed, a previous study of our laboratory demonstrated that the exogenous administration of OEA-prior to the onset of the neurodegenerative process-resulted in neuronal prot...

Oleoylethanolamide (OEA) is an endocannabinoid that has been proposed to prevent neuronal damage and neuroinflammation. In this study, we evaluated the effects of OEA on the disruption of both cerebellar structure and physiology and on the behavior of Purkinje cell degeneration (PCD) mutant mice. These mice exhibit cerebellar degeneration, displayi...